Procaps Group and Genomma Lab Announce a Strategic Agreement to Manufacture and Market Softgel Products in Latin America

Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated international healthcare and pharmaceutical services company, and Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB; “Genomma”), the leading pharmaceutical and personal care company in Latin America, today announced a strategic agreement to develop, manufacture and market five Softgel products within Latin America. Through this partnership, Procaps will manufacture and Genomma will market and distribute the products.

“Genomma’s strong core brands, proven business model and significant footprint throughout Latin America in the OTC market, make Genomma an ideal partner for our innovative oral delivery systems,” said Ruben Minski, CEO of Procaps Group. “This agreement results in a unique synergy to bolster our CDMO market share, especially in Mexico. We will also leverage Genomma’s precision multi-channel marketing and effective communication vehicles across a variety of media platforms to reach new customers.

“We’re excited to partner with Genomma, as this collaboration fits perfectly within our strategy to access new markets. We look forward to working with Genomma’s team to introduce our Softgel and gummies superior delivery system across their wide distribution network of independent and chain pharmacy retailers, wholesalers and e-commerce channel.”

Marco Sparvieri, CEO of Genomma Lab Internacional, added, “Our consumer-oriented marketing, broad retail distribution network, and low-cost, highly flexible operating model will support the rapid roll-out of these five Softgel products. This agreement creates additional synergies to bolster Genomma’s core competencies by offering additional pharmaceutical forms beyond those produced in our state-of-the art manufacturing complex in Mexico.” Mr. Sparvieri added, “Procaps’ innovative Softgel and gummies, will add new pharmaceutical formats to our premium branded product portfolio and lead to strong growth for both partners, laying the groundwork for new opportunities for growth.”

About Genomma Lab Internacional

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Latin America. Genomma Lab develops, sells and markets a broad range of Premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has a sound business model through a unique combination of a new product development process, consumer oriented marketing, a broad retail distribution network and a low‐cost, highly flexible supply chain operating model. For more information visit: www.genommalab.com